Telix Pharmaceuticals announces launch of Renal cancer imaging study
Category: #health  By Mateen Dalal  Date: 2019-08-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Telix Pharmaceuticals announces launch of Renal cancer imaging study
  • The pharmaceutical company declared the completion of CTN submission to Japanese PMDA for TLX250-CDx.
  • It is permitted to conduct Phase trials for renal cancer patients.

Australia based clinical-stage biopharmaceutical firm Telix Pharmaceuticals reportedly announced successful completion of a Clinical Trial Notification submission to the Japanese Pharmaceutical & Medical Devices Agency for TLX250-CDx.

For the uninitiated, Telix Pharmaceuticals Limited, headquartered in Australia is a biopharmaceutical company working towards the development of diagnostic and therapeutic products dependent on radiopharmaceuticals.

Reportedly, the company’s owned subsidiary Telix Japan had submitted the CTN at the July end following a robust consultation process with the PMDA. It has been claimed that the company tried resolving the PMDA’s remaining questions whilst collaborating with the other major shareholders like the Ministry of Health, and Labour and Welfare (MHLW).

As per trusted reports, Telix is now allowed to initiate a study designed to extend the company’s global ZIRCON Phase 3 investigation. It has been claimed that the study would register over 40 renal cancer patients. The phase 2 is expected to grow to a multi-focus study whilst operating under a procedure that is considered to be accurately identical to the ZIRCON investigation.

Speaking on the trial, the President of Telix Japan, Dr. Shintaro Nishimura reportedly stated that the company believes that CTN would wholly transform the face of the Japanese Nuclear Medicine community accounting to its first formal clinical investigation for the zirconium PET imaging in Japan. Additionally, TLX250-CDx offers an incredible potential to offer benefits to the cancer patients which would eventually help make way for impending use of theranostics in the country.

Meanwhile, the CEO of the company, Dr, Christian Behrenbruch cited that Telix has introduced a major amount to effort to accomplish the study and make it function in the states of Japan along with manufacturing the radiopharmaceutical products domestically within confined governing environment. Furthermore, the company is grateful to its clinical and finance partners for their constant support and involvement.

Source credit: https://www.globenewswire.com/news-release/2019/08/30/1908793/0/en/Telix-Pharmaceuticals-to-Launch-Japanese-Renal-Cancer-Imaging-Study.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
TPG Rise Climate Fund raises $5.4Bn to support new climate solutions
By Mateen Dalal

TPG Rise Climate Fund, the climate investing fund of TPG’s global impact investing platform TPG Rise, has recently raised its first close of $5.4 billion, bringing together an exclusive blend of funding from some of the top institutional invest...

Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
Baby nutrition firm ByHeart nabs $90Mn in Series B funding round
By Mateen Dalal

ByHeart, a fully integrated infant nutrition company, has reportedly secured $90 million in Series B funding which the company plans to use for the launch of its baby formula and support the development of its pipeline of nutrition items for chi...

UAE extends travel ban for Indians amid strict COVID-19 guidelines
UAE extends travel ban for Indians amid strict COVID-19 guidelines
By Mateen Dalal

United Arab Emirates (UAE) has reportedly extended travel ban for individuals travelling from India and several other south Asian countries on the pretext of COVID-19 guidelines. As reported by Etihad Airlines, the ban will be followed till 31st July...